These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37012275)

  • 1. Computational screening of FDA-approved drugs to identify potential TgDHFR, TgPRS, and TgCDPK1 proteins inhibitors against Toxoplasma gondii.
    Gharibi Z; Shahbazi B; Gouklani H; Nassira H; Rezaei Z; Ahmadi K
    Sci Rep; 2023 Apr; 13(1):5396. PubMed ID: 37012275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Insight into Effective Inhibitors' Binding to
    Vanichtanankul J; Yoomuang A; Taweechai S; Saeyang T; Pengon J; Yuvaniyama J; Tarnchompoo B; Yuthavong Y; Kamchonwongpaisan S
    ACS Chem Biol; 2022 Jul; 17(7):1691-1702. PubMed ID: 35715223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
    Hopper AT; Brockman A; Wise A; Gould J; Barks J; Radke JB; Sibley LD; Zou Y; Thomas S
    J Med Chem; 2019 Feb; 62(3):1562-1576. PubMed ID: 30624926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors.
    Ojo KK; Larson ET; Keyloun KR; Castaneda LJ; Derocher AE; Inampudi KK; Kim JE; Arakaki TL; Murphy RC; Zhang L; Napuli AJ; Maly DJ; Verlinde CL; Buckner FS; Parsons M; Hol WG; Merritt EA; Van Voorhis WC
    Nat Struct Mol Biol; 2010 May; 17(5):602-7. PubMed ID: 20436472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular docking to Toxoplasma gondii thymidylate synthase-dihydrofolate reductase and efficacy of raltitrexed in infected mice.
    de Paula Reis M; de Lima DA; Pauli KB; Andreotti CEL; de Moraes ALS; Gonçalves DD; Navarro IT; Bueno PSA; Seixas FAV; Gasparotto Junior A; Lourenço ELB
    Parasitol Res; 2018 May; 117(5):1465-1471. PubMed ID: 29550996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of ginsenoside Rh2 against Toxoplasma gondii infection-induced neuronal injury through binding TgCDPK1 and NLRP3 to inhibit microglial NLRP3 inflammasome signaling pathway.
    Jin GN; Lu JM; Lan HW; Lu YN; Shen XY; Xu X; Piao LX
    Int Immunopharmacol; 2022 Nov; 112():109176. PubMed ID: 36067653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ursolic acid derivatives with potential anti-Toxoplasma gondii activity.
    Zhang LH; Jin LL; Liu F; Jin C; Jin CM; Wei ZY
    Exp Parasitol; 2020 Sep; 216():107935. PubMed ID: 32569599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of protective immunity induced by recombinant calcium-dependent protein kinase 1 (TgCDPK1) protein against acute toxoplasmosis in mice.
    Huang SY; Chen K; Wang JL; Yang B; Zhu XQ
    Microb Pathog; 2019 Aug; 133():103560. PubMed ID: 31145981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homology modeling of dihydrofolate reductase from T. gondii bonded to antagonists: molecular docking and molecular dynamics simulations.
    Pacheco Homem D; Flores R; Tosqui P; de Castro Rozada T; Abicht Basso E; Gasparotto A; Augusto Vicente Seixas F
    Mol Biosyst; 2013 Jun; 9(6):1308-15. PubMed ID: 23450239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting prolyl-tRNA synthetase via a series of ATP-mimetics to accelerate drug discovery against toxoplasmosis.
    Yogavel M; Bougdour A; Mishra S; Malhotra N; Chhibber-Goel J; Bellini V; Harlos K; Laleu B; Hakimi MA; Sharma A
    PLoS Pathog; 2023 Feb; 19(2):e1011124. PubMed ID: 36854028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice.
    Chen J; Li ZY; Huang SY; Petersen E; Song HQ; Zhou DH; Zhu XQ
    BMC Infect Dis; 2014 Sep; 14():487. PubMed ID: 25192845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
    Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
    J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational heterogeneity in apo and drug-bound structures of Toxoplasma gondii prolyl-tRNA synthetase.
    Mishra S; Malhotra N; Kumari S; Sato M; Kikuchi H; Yogavel M; Sharma A
    Acta Crystallogr F Struct Biol Commun; 2019 Nov; 75(Pt 11):714-724. PubMed ID: 31702585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.
    Vidadala RS; Rivas KL; Ojo KK; Hulverson MA; Zambriski JA; Bruzual I; Schultz TL; Huang W; Zhang Z; Scheele S; DeRocher AE; Choi R; Barrett LK; Siddaramaiah LK; Hol WG; Fan E; Merritt EA; Parsons M; Freiberg G; Marsh K; Kempf DJ; Carruthers VB; Isoherranen N; Doggett JS; Van Voorhis WC; Maly DJ
    J Med Chem; 2016 Jul; 59(13):6531-46. PubMed ID: 27309760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.
    Zhang HB; Shen QK; Wang H; Jin C; Jin CM; Quan ZS
    Eur J Med Chem; 2018 Oct; 158():414-427. PubMed ID: 30237124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutics for
    Wu RZ; Zhou HY; Song JF; Xia QH; Hu W; Mou XD; Li X
    J Med Chem; 2021 Dec; 64(24):17627-17655. PubMed ID: 34894691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic pathway analysis and molecular docking analysis for identification of putative drug targets in Toxoplasma gondii: novel approach.
    Gautam B; Singh G; Wadhwa G; Farmer R; Singh S; Singh AK; Jain PA; Yadav PK
    Bioinformation; 2012; 8(3):134-41. PubMed ID: 22368385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspective on current and emerging drugs in the treatment of acute and chronic toxoplasmosis.
    Lapinskas PJ; Ben-Harari RR
    Postgrad Med; 2019 Nov; 131(8):589-596. PubMed ID: 31399001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of potent inhibitors against chorismate synthase of Toxoplasma gondii using molecular dynamics simulations.
    Singh S; Qureshi IA
    J Mol Graph Model; 2022 Jul; 114():108183. PubMed ID: 35405440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.